Companion Diagnostics Market Research Report by Technology (Immunohistochemistry, In Situ Hybridization, and Next-generation Sequencing), by Indication (Breast Cancer, Colorectal Cancer, and Leukemia), by End User, by Region (Americas, Asia-Pacific, and E

Companion Diagnostics Market Research Report by Technology (Immunohistochemistry, In Situ Hybridization, and Next-generation Sequencing), by Indication (Breast Cancer, Colorectal Cancer, and Leukemia), by End User, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

The Global Companion Diagnostics Market size was estimated at USD 1,906.47 million in 2020 and expected to reach USD 2,116.56 million in 2021, at a CAGR 11.35% to reach USD 3,635.54 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.


Market Segmentation & Coverage:

This research report categorizes the Companion Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the market was studied across Immunohistochemistry, In Situ Hybridization, Next-generation Sequencing, and Polymerase Chain Reaction.

Based on Indication, the market was studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, and Melanoma.

Based on End User, the market was studied across Biopharmaceutical Companies, Pharmaceutical, and Reference Laboratories.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Companion Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Companion Diagnostics Market, including Abbott Laboratories, Abnova Corporation, Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., Archerdx, Inc., ARUP Laboratories, Biogenex Laboratories, Inc, bioMérieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, FOUNDATION MEDICINE, INC., Guardant Health, Inc, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, Q2 Solutions, R-Biopharm AG, Siemens Healthcare Private Limited, Sysmex Corporation, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Companion Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Companion Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Companion Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Companion Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Companion Diagnostics Market?
6. What is the market share of the leading vendors in the Global Companion Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Companion Diagnostics Market?


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Introduction
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Increasing prevalence of chronic diseases
5.2.2. Growing demand for personalized medicines and targeted therapy
5.3. Restraints
5.3.1. High costs of companion diagnostics
5.4. Opportunities
5.4.1. Technological advancements in diagnostic techniques
5.4.2. Growing approval rate for companion diagnostics
5.5. Challenges
5.5.1. Reimbursement issues associated with companion diagnostic tests
6. Companion Diagnostics Market, by Technology
6.1. Introduction
6.2. Immunohistochemistry
6.3. In Situ Hybridization
6.4. Next-generation Sequencing
6.5. Polymerase Chain Reaction
7. Companion Diagnostics Market, by Indication
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Leukemia
7.5. Lung Cancer
7.6. Melanoma
8. Companion Diagnostics Market, by End User
8.1. Introduction
8.2. Biopharmaceutical Companies
8.3. Pharmaceutical
8.4. Reference Laboratories
9. Americas Companion Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Companion Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Companion Diagnostics Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.2. Abnova Corporation
13.3. Agilent Technologies, Inc.
13.4. Almac Group
13.5. Amoy Diagnostics Co., Ltd.
13.6. Archerdx, Inc.
13.7. ARUP Laboratories
13.8. Biogenex Laboratories, Inc
13.9. bioMérieux SA
13.10. Danaher Corporation
13.11. Eli Lilly and Company
13.12. F. Hoffmann-La Roche AG
13.13. FOUNDATION MEDICINE, INC.
13.14. Guardant Health, Inc
13.15. Illumina, Inc.
13.16. Invivoscribe Technologies, Inc.
13.17. Myriad Genetics, Inc.
13.18. NG biotech
13.19. Q2 Solutions
13.20. R-Biopharm AG
13.21. Siemens Healthcare Private Limited
13.22. Sysmex Corporation
13.23. Thermo Fisher Scientific Inc.
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET: MARKET DYNAMICS
FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (%)
FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2026
FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2026 (USD MILLION)
FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2026 (USD MILLION)
FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
FIGURE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2026
FIGURE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2026 (USD MILLION)
FIGURE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2026 (USD MILLION)
FIGURE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY MELANOMA, 2018-2026 (USD MILLION)
FIGURE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY MELANOMA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 28. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 29. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2026
FIGURE 31. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2026 (USD MILLION)
FIGURE 32. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 33. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL, 2018-2026 (USD MILLION)
FIGURE 34. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 35. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, 2018-2026 (USD MILLION)
FIGURE 36. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 37. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 38. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 39. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 40. CANADA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 41. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 42. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 43. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 44. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 45. CHINA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 46. INDIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 47. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 48. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 49. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 50. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 51. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 52. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 53. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 54. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 56. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 57. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 58. ITALY COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 59. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 60. QATAR COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 61. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 63. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 64. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 65. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 66. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 67. GLOBAL COMPANION DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 68. GLOBAL COMPANION DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 69. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL COMPANION DIAGNOSTICS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL COMPANION DIAGNOSTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2026 (USD MILLION)
TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2026 (USD MILLION)
TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
TABLE 19. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 20. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 21. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 22. CANADA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 23. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 24. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 25. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 26. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. CHINA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. INDIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. ITALY COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. QATAR COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 46. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 47. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 48. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 49. GLOBAL COMPANION DIAGNOSTICS MARKET: SCORES
TABLE 50. GLOBAL COMPANION DIAGNOSTICS MARKET: BUSINESS STRATEGY
TABLE 51. GLOBAL COMPANION DIAGNOSTICS MARKET: PRODUCT SATISFACTION
TABLE 52. GLOBAL COMPANION DIAGNOSTICS MARKET: RANKING
TABLE 53. GLOBAL COMPANION DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 54. GLOBAL COMPANION DIAGNOSTICS MARKET: MERGER & ACQUISITION
TABLE 55. GLOBAL COMPANION DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 56. GLOBAL COMPANION DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 57. GLOBAL COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING
TABLE 58. GLOBAL COMPANION DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 59. GLOBAL COMPANION DIAGNOSTICS MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook